Guide RNA (sgRNA) sequences are shown (e). Western blot analysis of GPT2 protein in parental cells and two independently-derived GPT2 knockout clones (f). GPT2 knockout clones grow slower than parental cells. Cell proliferation was assayed by counting cell number for five consecutive days (g). Compared to parental cells, GPT2 knockout clones are more resistant to glutamine deprivation. Cells were grown with or without glutamine for 3 days and apoptotic cells were measured by FACS analysis of sub-G1 cell population (h). (j) to (l) Reconstitution of GPT2 in GPT2 knockout cells makes them more sensitive to glutamine deprivation. GPT2 knockout clone 1 (KO-1) was transfected with a plasmid expressing GPT2. Stable pools were selected. Western blot shows re-expression of GPT2 (i). Reconstitution of GPT2 makes the knockout cells grow faster (j). Cells of the indicated genotypes were grown with or without glutamine for 72 hours. Apoptotic cells were quantified (k). (m)to (n) Knockdown of GPT2 in a HCT116 PIK3CA WT clone has no impact on sensitivity to glutamine deprivation. HCT116 PIK3CA WT cells was transfected with control shRNA or two independent shRNA against GPT2. Stable pools were selected. Knockdown of GPT2 was confirmed by Western blots analysis (l). Cell proliferation was assayed by counting cell number for five consecutive days (m). Cells were grown with or without glutamine for 3 days and apoptotic cells were measured by FACS analysis of sub-G1 cell population (n). (p) Overexpression (OE) of WT GPT2, but not inactive mutant, in the HCT116 PIK3CA WT clone makes them more sensitive to glutamine deprivation. Equal numbers of cells expressing WT or enzymatically inactive GPT2 were grown in medium without glutamine and cell numbers were counted for five consecutive days.
WT clone (WT1). Three million cells were injected subcutaneously and bilaterally into athymic nude mice. Once tumors reached an average size of 100 mm 3 , 10 mg/kg of AOA was injected IP once a day for two weeks. (c) AOA treatment reduces amounts of α-ketoglutarate and alanine, but increases amounts of glutamine, glutamate and pyruvate, in tumors formed by HCT116 PIK3CA mutant cells. Xenograft tumors were treated with vehicle or 10 mg/kg of AOA daily for 2 weeks. Tumors were harvested and the indicated metabolites were measured by GC-MS. N = 4 tumors for each group. a.u.: arbitrary unit. * p < 0.05; ** p < 0.01; t test. 
